Oxford Gene Technology Awarded £1.2m Genomics England Contract
Oxford Gene Technology (OGT) announced it has been awarded a £1.2m phase two Small Business Research Initiative (SBRI) Healthcare contract. The contract is to develop next generation sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK.
Development of this technology will increase the accuracy and ease of interpreting whole genome genetic variant data by clinicians, supporting more precise treatment decisions. In addition to the analysis of NGS data, the software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH). The results of these tests will be put in context via the use of both public and private databases, providing the clinician with prioritised clinically-relevant results. These easy-to-understand reports will support faster diagnosis and better patient care.
James Clough, Executive Vice President Commercial, OGT said: “The award of this £1.2m contract underlines OGT’s position as a leading developer of cutting-edge products for molecular genetics. OGT has customers in over 60 countries worldwide and will use its extensive sales and marketing infrastructure to successfully commercialise the resulting product.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
ZEISS and RIKEN Innovation establish partnership in bioengineering and data management - Synergizing RIKEN's excellence in basic research in bioengineering with ZEISS's expertise in imaging and sensing
Fred_Landeg
Recommendation against combined use of medicines affecting the renin-angiotensin system
Category:Causinae_by_common_name
Al-Kindi
Society for Clinical Data Management (SCDM) - Brüssel, Belgium
Category:KAZAL_domain
Stealth-adapted_virus
